Orchestra BioMed Holdings (OBIO) Income from Continuing Operations (2021 - 2026)
Orchestra BioMed Holdings' (OBIO) quarterly Income from Continuing Operations came in at 24755000.0 in Q1 2026, down 27.72% year-on-year from 34246389.62 in Q1 2025, and down 487.22% on a QoQ basis from 6393000.0 in Q4 2025.
Orchestra BioMed Holdings (OBIO) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 6 years of Income from Continuing Operations data on file, last reported at 24755000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 27.72% year-over-year to 24755000.0 in Q1 2026; TTM through Mar 2026 was 60468000.0, a 22.77% increase from a year earlier, with the FY2025 full-year figure at 160078000.0, down 1.18% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 24755000.0, down from 6393000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for OBIO reached as high as 6393000.0 in Q4 2025 and fell as low as 25188000.0 in Q2 2024.
- Historically, Income from Continuing Operations has averaged 14794000.0 across 5 years, with a median of 16098000.0 in 2024.
- Across the five-year window, Income from Continuing Operations slumped 8300.5% in 2022 and jumped 139.71% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 10159000.0 in 2022, then decreased by 20.09% to 12200000.0 in 2023, then sank by 31.95% to 16098000.0 in 2024, then jumped by 139.71% to 6393000.0 in 2025, then tumbled by 487.22% to 24755000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 24755000.0 in Q1 2026, 6393000.0 in Q4 2025, and 20538000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Orchestra BioMed Holdings | 235.83 Mn | 141.43 Mn | 78,000.00 | -24.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.76 Mn |
| Dec 31, 2025 | 6.39 Mn |
| Sep 30, 2025 | -20.54 Mn |
| Jun 30, 2025 | -21.57 Mn |
| Mar 31, 2025 | -19.38 Mn |
| Dec 31, 2024 | -16.10 Mn |
| Sep 30, 2024 | -17.62 Mn |
| Jun 30, 2024 | -25.19 Mn |
| Mar 31, 2024 | -15.80 Mn |
| Dec 31, 2023 | -12.20 Mn |
| Sep 30, 2023 | -22.02 Mn |
| Jun 30, 2023 | -16.96 Mn |
| Mar 31, 2023 | -11.90 Mn |
| Dec 31, 2022 | -10.16 Mn |
| Sep 30, 2022 | -10.45 Mn |
| Jun 30, 2022 | -7.89 Mn |
| Mar 31, 2022 | -5.36 Mn |
| Dec 31, 2021 | -122,045.00 |
| Sep 30, 2021 | -124,445.00 |
| Jun 30, 2021 | -126,318.00 |